{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:18:57Z","timestamp":1759515537711,"version":"3.44.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.therap.2021.04.008","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T14:29:09Z","timestamp":1619015349000},"page":"705-714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hypophosphat\u00e9mie et fer injectable\u00a0: \u00e0 propos d\u2019un cas et revue de la litt\u00e9rature"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8630-961X","authenticated-orcid":false,"given":"Anne-Lise","family":"Lecoq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Becquemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.therap.2021.04.008_bib0235","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2013-06-508325","article-title":"A systematic analysis of global anemia burden from 1990\u00a0to 2010","volume":"123","author":"Kassebaum","year":"2014","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.therap.2021.04.008_bib0240","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1401038","article-title":"Iron-deficiency anemia","volume":"372","author":"Camaschella","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.therap.2021.04.008_bib0245","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/j.1537-2995.2009.02327.x","article-title":"Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial","volume":"49","author":"Van Wyck","year":"2009","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.therap.2021.04.008_bib0250","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/trf.12289","article-title":"A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia","volume":"54","author":"Onken","year":"2014","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.therap.2021.04.008_bib0255","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/ndt\/gfv293","article-title":"A randomized trial of iron isomaltoside 1000\u00a0versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia","volume":"31","author":"Kalra","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.therap.2021.04.008_bib0260","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.crohns.2010.01.007","article-title":"The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective","volume":"4","author":"Bager","year":"2010","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.therap.2021.04.008_bib0265","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/asheducation-2010.1.338","article-title":"Clinical use of intravenous iron: administration, efficacy, and safety","volume":"2010","author":"Auerbach","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"11","key":"10.1016\/j.therap.2021.04.008_bib0270","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2169\/naika.71.1566","article-title":"Two cases of non-specific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide","volume":"71","author":"Okada","year":"1982","journal-title":"Nihon Naika Gakkai Zasshi"},{"issue":"2","key":"10.1016\/j.therap.2021.04.008_bib0275","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF01496662","article-title":"Hypophosphatemia induced by intravenous administration of Saccharated iron oxide","volume":"61","author":"Okada","year":"1983","journal-title":"Klin Wochenschr"},{"issue":"3","key":"10.1016\/j.therap.2021.04.008_bib0280","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jbmr.3369","article-title":"Iron supplementation-induced phosphaturic osteomalacia: FGF23\u00a0is the culprit","volume":"33","author":"Urbina","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.therap.2021.04.008_bib0285","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","article-title":"Pharmacovigilance \u2013 The next chapter","volume":"74","author":"Moore","year":"2019","journal-title":"Therapie"},{"issue":"4","key":"10.1016\/j.therap.2021.04.008_bib0290","doi-asserted-by":"crossref","first-page":"435e1","DOI":"10.1016\/j.ajog.2008.07.046","article-title":"Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial","volume":"199","author":"Seid","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.therap.2021.04.008_bib0295","doi-asserted-by":"crossref","first-page":"846e1","DOI":"10.1053\/j.gastro.2011.06.005","article-title":"FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease","volume":"141","author":"Evstatiev","year":"2011","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.therap.2021.04.008_bib0300","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/apt.14043","article-title":"Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease","volume":"45","author":"Aksan","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"Pt 2","key":"10.1016\/j.therap.2021.04.008_bib0305","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1258\/acb.2008.008151","article-title":"Iron polymaltose-induced FGF23\u00a0elevation complicated by hypophosphataemic osteomalacia","volume":"46","author":"Schouten","year":"2009","journal-title":"Ann Clin Biochem"},{"issue":"7","key":"10.1016\/j.therap.2021.04.008_bib0310","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/TP.0b013e3181f00a18","article-title":"Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient","volume":"90","author":"Mani","year":"2010","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.therap.2021.04.008_bib0315","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ejcn.2014.20","article-title":"Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient","volume":"68","author":"Fierz","year":"2014","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.therap.2021.04.008_bib0320","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-219160","article-title":"Severe hypophosphataemia after intravenous iron administration","volume":"2017","author":"Anand","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.therap.2021.04.008_bib0325","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1053\/j.gastro.2016.09.050","article-title":"Blood and bone loser","volume":"152","author":"Schaefer","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.therap.2021.04.008_bib0330","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jbmr.3319","article-title":"Hypophosphatemia, severe bone pain, gait disturbance, and fatigue fractures after iron substitution in inflammatory bowel disease: a case report","volume":"33","author":"Bartko","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.therap.2021.04.008_bib0335","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/jbmr.3372","article-title":"Re: Hypophosphatemia, severe bone pain, gait disturbance, and fatigue fractures after iron substitution in inflammatory bowel disease: a case report","volume":"33","author":"Tournis","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.therap.2021.04.008_bib0340","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222851","article-title":"Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration","volume":"2018","author":"Klein","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"19","key":"10.1016\/j.therap.2021.04.008_bib0345","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.jacc.2018.03.448","article-title":"High-dose ferric carboxymaltose in patients with HFrEF induces significant hypophosphatemia","volume":"71","author":"St\u00f6hr","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.therap.2021.04.008_bib0350","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.endinu.2018.10.006","article-title":"Intravenous iron induced severe hypophophatemia in a gastric bypass patient","volume":"66","author":"G\u00f3mez Rodr\u00edguez","year":"2019","journal-title":"Endocrinol Diabetes Nutr"},{"issue":"4","key":"10.1016\/j.therap.2021.04.008_bib0355","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","article-title":"Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia","volume":"45","author":"Shimizu","year":"2009","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.therap.2021.04.008_bib0360","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/ndt\/gfv096","article-title":"A randomized, open-label trial of iron isomaltoside 1000 (Monofer\u00ae) compared with iron sucrose (Venofer\u00ae) as maintenance therapy in haemodialysis patients","volume":"30","author":"Bhandari","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.therap.2021.04.008_bib0365","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/phar.1729","article-title":"A randomized non-inferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with non-myeloid malignancies and anemia receiving chemotherapy: the PROFOUND trial","volume":"36","author":"Birgeg\u00e5rd","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.therap.2021.04.008_bib0370","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.24633","article-title":"A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia","volume":"92","author":"Derman","year":"2017","journal-title":"Am J Hematol"},{"issue":"23","key":"10.1016\/j.therap.2021.04.008_bib0375","doi-asserted-by":"crossref","first-page":"e124486","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.therap.2021.04.008_bib0380","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12916-020-01643-5","article-title":"Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose \u2013 the randomized controlled HOMe aFers study","volume":"18","author":"Emrich","year":"2020","journal-title":"BMC Med"},{"issue":"8","key":"10.1016\/j.therap.2021.04.008_bib0385","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23\u00a0and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.therap.2021.04.008_bib0390","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.therap.2021.04.008_bib0395","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tmrv.2020.07.002","article-title":"Comparative risk of hypophosphatemia following the administration of intravenous iron formulations: a network meta-analysis","volume":"34","author":"Bellos","year":"2020","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.therap.2021.04.008_bib0400","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside \u2013 a systematic review and meta-analysis","author":"Schaefer","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.therap.2021.04.008_bib0405","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/apt.15386","article-title":"Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside","volume":"50","author":"Detlie","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.therap.2021.04.008_bib0410","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/bcp.13189","article-title":"Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions","volume":"83","author":"Bager","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2021.04.008_bib0415","doi-asserted-by":"crossref","first-page":"468675","DOI":"10.1155\/2015\/468675","article-title":"Intravenous iron administration and hypophosphatemia in clinical practice","volume":"2015","author":"Hardy","year":"2015","journal-title":"Int J Rheumatol"},{"issue":"12","key":"10.1016\/j.therap.2021.04.008_bib0420","doi-asserted-by":"crossref","first-page":"e0167146","DOI":"10.1371\/journal.pone.0167146","article-title":"Choice of high-dose intravenous iron preparation determines hypophosphatemia risk","volume":"11","author":"Schaefer","year":"2016","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.therap.2021.04.008_bib0425","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/rheumatology\/kez627","article-title":"Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia","volume":"59","author":"Amarnani","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.therap.2021.04.008_bib0430","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1507\/endocrj.45.431","article-title":"Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy","volume":"45","author":"Sato","year":"1998","journal-title":"Endocr J"},{"issue":"11","key":"10.1016\/j.therap.2021.04.008_bib0435","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23\u00a0as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.therap.2021.04.008_bib0440","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23\u00a0is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.therap.2021.04.008_bib0445","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1210\/jc.2012-1811","article-title":"Biological variability of plasma intact and C-terminal FGF23\u00a0measurements","volume":"97","author":"Smith","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.therap.2021.04.008_bib0450","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23\u00a0at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.therap.2021.04.008_bib0455","doi-asserted-by":"crossref","first-page":"115559","DOI":"10.1016\/j.bone.2020.115559","article-title":"Effects of ferric carboxymaltose on markers of mineral and bone metabolism: a single-center prospective observational study of women with iron deficiency","volume":"141","author":"Frazier","year":"2020","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.therap.2021.04.008_bib0230","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/imj.13001","article-title":"Severe hypocalcaemia and hypophosphataemia following intravenous iron and denosumab: a novel drug interaction","volume":"46","author":"Smyth","year":"2016","journal-title":"Intern Med J"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721001049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721001049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:15Z","timestamp":1758567315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595721001049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0040595721001049"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2021.04.008","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypophosphat\u00e9mie et fer injectable\u00a0: \u00e0 propos d\u2019un cas et revue de la litt\u00e9rature","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2021.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}